Search

Dexpramipexole

to the End of the T Wave Corrected for Heart Rate)). … investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex

Deutivacaftor

Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.

2-Hydroxylpropyl-beta-cyclodextrin

Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

Dextromethadone

Dextromethadone is under investigation in clinical trial NCT00588640 (Study of D-Methadone in Patients With Chronic Pain).

Avapritinib

[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

Pafolacianine

Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.

Benzhydrocodone

Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

Ferric chloride

Brensocatib

[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

Cobaltous sulfate